Higher prevalence of osteoporotic manifestations in men with indolent systemic mastocytosis
THURSDAY, Jan. 19 (HealthDay News) -- There is a high risk of osteoporotic fractures and osteoporosis in patients with indolent systemic mastocytosis (ISM), according to a study published online Jan. 9 in Allergy.
Eveline van der Veer, M.D., Ph.D., of the University of Groningen Medical Center in the Netherlands, and colleagues assessed osteoporotic fracture prevalence in 65 men and 92 women (mean age, 54 years) with ISM, using vertebral morphometry, medical records, and questionnaires. They also measured bone mineral density of the lumbar spine and femoral neck and analyzed tryptase, urinary histamine metabolites, methylhistamine (MH), and methylimidazole acetic acid.
The researchers identified 235 lifetime fractures, including 140 low-energy trauma osteoporotic fractures, in 154 patients with ISM. Osteoporotic fractures were seen in 37 percent of patients, and osteoporosis was seen in 28 percent. These osteoporotic manifestations were seen in 46 percent of men younger than 50 years and 73 percent aged 50 or older, compared with 18 percent of women younger than 50 years and 58 percent aged 50 or older. Higher urinary MH, older age, and male gender were independently related to the prevalence of osteoporotic manifestations.
"Efforts should be made to optimize bone quality by at least ensuring adequate vitamin D and calcium intake in all patients with ISM, especially the younger ones, and by adequate drug treatment in the patients with osteoporosis to reduce the risk of fractures," the authors write.
Full Text (subscription or payment may be required)